2-isopropyl-2,3-dihydrobenzofuran | 74695-08-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: 2-isopropyl-2,3-dihydrobenzofuran
• 英文别名: 2-propan-2-yl-2,3-dihydro-1-benzofuran
• CAS: 74695-08-2；91969-36-7
• 化学式: C₁₁H₁₄O
• 分子量: 162.232
• InChiKey: QKFFZNPEDJETGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  水杨醇 在 偶氮二甲酸二异丙酯 、 lithium 、 对甲苯磺酸 、 sodium sulfate 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 14.0h， 生成 2-isopropyl-2,3-dihydrobenzofuran
  参考文献：
  名称：

  2-羟基和2-巯基苄醇的新同系物

  摘要：

  苯并-1,3-二恶烷或苯并-1,3-氧杂蒽1 [由2-羟基或2-巯基苄基醇（分别为3或4）和羰基化合物容易制得]与过量的锂和α在室温或-78°C下，DTBB在THF中的催化量（4.5摩尔％）导致水解后生成相应的均苄醇2。在酸性（85％H 3 PO 4）或中性（Ph 3 P / DIAD）条件下将化合物2环化，可得到预期的杂环5。

  DOI：

  10.1016/s0040-4020(97)10161-2

文献信息

• Hepatitis C Virus Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US20130183269A1

  公开（公告）日：2013-07-18

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组成物，以及抑制NS5A蛋白功能的方法。
• PYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN-INHIBITORY ACTIVITY
  申请人：The University of Tokyo

  公开号：US20170158704A1

  公开（公告）日：2017-06-08

  A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: wherein R 1 , R 2 , R 3 , R 4a , R 4c , R 5 are as defined in the description.

  根据公式（Ia）至（Ic）中的任一化合物或其药学上可接受的盐： 其中R1、R2、R3、R4a、R4c、R5如描述中所定义。
• Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150307465A1

  公开（公告）日：2015-10-29

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

  本发明提供了多种形式的亚氨基噻二唑二氧化物化合物，包括公式(I)的化合物： 包括它们的立体异构体，以及所述立体异构体的药用可接受盐，其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-都是独立选择且按本文定义。发明的新型亚氨基噻二唑二氧化物化合物出人意料地被发现具有预期的特性，使其作为BACE抑制剂以及/或用于治疗和预防与β-淀粉样蛋白（“Aβ”）生成相关的各种病理学具有优势。还公开了包含一个或多个此类化合物（单独使用和与一个或多个其他活性成分组合使用）的药物组合物，以及它们的制备方法和用于治疗与淀粉样β（Aβ）蛋白相关的病理学，包括阿尔茨海默病的方法。
• NOVEL OLEFIN DERIVATIVE
  申请人：Matsumura Akira

  公开号：US20150246938A1

  公开（公告）日：2015-09-03

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I′): wherein R 1 is substituted or unsubstituted aryl etc., R 2 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 3 is each independently hydrogen, substituted or unsubstituted alkyl etc., n is an integer from 0 to 3, R 12 is hydrogen, substituted or unsubstituted alkyl etc., Ring A is aromatic carbocycle or aromatic heterocycle, R 9 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., m is an integer from 0 to 4, R 4 and R 5 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 6 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., R 13 is hydrogen, substituted or unsubstituted alkyl etc., X 5 is bond etc., R 7 is hydrogen or substituted or unsubstituted alkyl, R 8 is substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl etc.

  本发明的目的是提供具有ACC2抑制活性的新型化合物。此外，本发明的目的是提供包含该化合物的药物组合物。 公式(I′)的化合物： 其中R1是取代或未取代的芳基等， R2各自独立为氢，取代或未取代的烷基等， R3各自独立为氢，取代或未取代的烷基等， n是0到3的整数， R12是氢，取代或未取代的烷基等， 环A是芳香碳环或芳香杂环， R9是取代或未取代的烷基，取代或未取代的烯基等， m是0到4的整数， R4和R5各自独立为氢，取代或未取代的烷基等， R6是取代或未取代的烷基，取代或未取代的烯基等， R13是氢，取代或未取代的烷基等， X5是键等， R7是氢或取代或未取代的烷基， R8是取代或未取代的烷基碳酰，取代或未取代的烯基碳酰等。
• Ruthenium NHC Catalyzed Highly Asymmetric Hydrogenation of Benzofurans
  作者：Nuria Ortega、Slawomir Urban、Bernhard Beiring、Frank Glorius

  DOI：10.1002/anie.201107811

  日期：2012.2.13

  H2‐O‐T! Aromatic O‐heterocycles are a challenging substrates for asymmetric hydrogenation (H2). An in situ formed chiral N‐heterocyclic carbene (NHC) ruthenium complex allows the high yielding, completely regioselective, and highly asymmetric hydrogenation of substituted benzofurans at room Temperature, giving valuable 2,3‐dihydrobenzofurans (see scheme).

  H 2 ‐O‐T！芳族O杂环是不对称氢化（H 2）的具有挑战性的底物。原位形成的手性N-杂环卡宾（NHC）钌络合物可在T温度下以高收率，完全区域选择性和高度不对称氢化取代苯并呋喃，得到有价值的2,3-二氢苯并呋喃（参见方案）。